Taiwanese drug developer Senhwa Biosciences said Sunday that its investigational drug for the treatment of severe COVID-19 infections has received positive reviews from an independent monitoring group in the United States, and its clinical trials can go forward.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
- Politics
Taiwan names foreign ministry's chief secretary as new envoy to Ireland
05/04/2025 02:33 PM - Politics
Taiwan congratulates Singapore after ruling party wins another election
05/04/2025 12:40 PM - Society
Taiwan headline news
05/04/2025 12:10 PM - Society
Rain showers forecast for northern, eastern Taiwan Sunday
05/04/2025 10:36 AM - Politics
Two KMT staffers detained in Taichung recall cases
05/03/2025 09:44 PM